Beam Therapeutics
BEAM
237 hedge funds and large institutions have $1.99B invested in Beam Therapeutics in 2025 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 102 increasing their positions, 47 reducing their positions, and 32 closing their positions.
117% more repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 47
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
52% more call options, than puts
Call options by funds: $11.8M | Put options by funds: $7.81M
28% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 32
3.19% more ownership
Funds ownership: 98.36% → 101.55% (+3.2%)
3% more funds holding
Funds holding: 231 → 237 (+6)
2% less capital invested
Capital invested by funds: $2.02B → $1.99B (-$34.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$121M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$45.1M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$44.2M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$37M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$33.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$9.37M |
| 2 |
YCM
Yiheng Capital Management
San Francisco,
California
|
-$9.35M |
| 3 |
Jane Street
New York
|
-$7.28M |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$5.16M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.8M |
BEAM Hedge Fund Activity: Q1 2025 in Review
237 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q1 2025, worth a combined $1.99B — down 1.7% from $2.02B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new BEAM positions and 32 closed out — a net gain of 9 holders — while 102 added to existing stakes and 47 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $121M. The largest seller was UBS Group, cutting an estimated $9.37M.
- 237 institutional investors held Beam Therapeutics (BEAM) as of Q1 2025, up from 231 in Q4 2024.
- Funds reported $1.99B of Beam Therapeutics stock for Q1 2025, down 1.7% quarter-over-quarter.
- 41 funds opened new Beam Therapeutics positions in Q1 2025 and 32 closed out, a net change of +9 holders.
- The largest Beam Therapeutics buyer in Q1 2025 was Fidelity Investments, an estimated $121M added.
- The largest Beam Therapeutics seller in Q1 2025 was UBS Group, an estimated $9.37M sold.
Based on aggregated 13F filings for Q1 2025.